IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingIQV
Artificial Intelligence▲
Veeva Reports Record Q2 Revenue of $928 Million
Veeva Systems reported a record second quarter for fiscal 2027, with total revenue of $928 million and non-GAAP operating income of $416 million, both exceeding guidance. The company achieved its best-ever CRM quarter, with two TOP20 biopharma customers, Lilly and Biogen, selecting Vault CRM, bringing the total to 12 of TOP20. Veeva Falcon, its agentic AI product, is generating high customer interest, with early adopters showing promising results and faster implementation. Commercial subscription revenue grew 13% year-over-year, with broad-based strength across CRM, content, data, and Crossix. The company also highlighted progress with its Aspen product, priced at $50 per user per month, and its partnership with IQVIA, which CEO Peter Gassner called one of the best things to happen to Veeva in the past 12 months.
Repligen reported second-quarter revenues of $204.1 million, up 11.9% year over year and exceeding analysts' expectations by 1.1%. The company also beat analysts' EPS and organic revenue estimates, with President and CEO Olivier Loeillot citing 13% organic growth and increased full-year guidance. Among the eight drug development inputs and services stocks tracked, the group's revenues beat consensus estimates by 4.1% on average, while next quarter's revenue guidance came in 0.8% above expectations. Repligen delivered the weakest performance against analyst estimates and the weakest full-year guidance update of the group, yet its stock is up 29.4% since reporting and currently trades at $169.56. Azenta posted the best Q2 with revenues of $161.2 million, up 12% year over year and beating estimates by 8%, while IQVIA reported revenues of $4.37 billion, up 8.7% year over year and exceeding expectations by 1.5%.
IQVIA Stock Jumps 42% in Three Months on Strong Bookings and Raised Outlook
IQVIA Holdings shares have rallied 41.5% over the past three months, outperforming the industry's 17.2% growth and the S&P 500's 3.4% uptick. The company reported net new bookings of $3.2 billion for research and development solutions in the second quarter of 2026, up 19% year over year and yielding a book-to-bill ratio of 1.22X. Its contracted backlog stood at $34.2 billion as of June 30, 2026, with $9.2 billion expected to convert to revenue in the next 12 months. Management raised full-year revenue guidance to $17.28-$17.48 billion and earnings guidance to $12.8-$13 per share. IQVIA repurchased $950 million of shares in the first half of 2026 after buying back $1.24 billion in 2025.
IQVIA raises 2026 revenue guidance to $17.28–$17.48 billion
IQVIA Holdings raised its full-year 2026 revenue guidance to between US$17.28 billion and US$17.48 billion alongside its second-quarter results, which showed higher sales but relatively flat net income and EPS. The company also announced a collaboration with Medera that pairs IQVIA's global clinical and commercialization infrastructure with Medera's Sardocor and Novoheart cardiac gene therapy and human-based drug discovery platforms, focusing on AAV-based cardiac gene therapies and the mini-Heart platform under the FDA Modernization Act 2.0. IQVIA continued share repurchases during the period. The partnership reinforces IQVIA's push into cell and gene therapy and human-based R&D solutions, though it does not materially change the near-term catalyst of AI and real-world evidence adoption. Investors remain focused on whether strong demand and specialized partnerships can translate into sustained earnings growth amid mix shifts and margin pressures.
Global eClinical Solutions Market to Reach USD 42.55 Billion by 2035
The global eClinical solutions market is projected to grow from USD 11.50 billion in 2025 to USD 42.55 billion by 2035, at a compound annual growth rate of 13.98 percent, according to a report by Healthcare Foresights. The market was valued at approximately USD 11.50 billion in 2025 and is expected to reach USD 13 billion in 2026. Key players include Oracle, IQVIA, Veeva Systems, and Medidata Solution Inc. North America currently dominates the market, while the Asia-Pacific region is expected to see the highest growth rate. The report segments the market by product, delivery mode, development phase, and region.
IQVIA Posts Record $3.15 Billion in Clinical Bookings, Raises 2026 Guidance
IQVIA Holdings reported record net new bookings of $3.15 billion in its Research & Development Solutions division for the second quarter of 2026, driving an 8.8% pre-market share jump. Total revenue rose 8.7% year-over-year to $4.368 billion, while adjusted diluted earnings per share increased 12.1% to $3.15, beating consensus estimates. The company raised its full-year 2026 guidance, now expecting revenue between $17.275 billion and $17.475 billion and adjusted EPS of $12.80 to $13.00. The contracted backlog reached a record $34.2 billion, with a trailing-twelve-month book-to-bill ratio of 1.22x, and free cash flow grew 23.3% to $360 million during the quarter.
IQVIA CEO Ari Bousbib Sold $26.1 Million in Shares as Bookings Hit Record $3.15 Billion
IQVIA Holdings Chairman and CEO Ari Bousbib sold about 106,000 shares for total proceeds of $26.1 million, according to an SEC filing. The transaction was an exercise-and-sell of stock appreciation rights expiring in February 2027, with shares sold at a weighted average price of $245.51, a narrow discount to the July 29 market close of $247.56. Bousbib retains a total beneficial position of 1.4 million shares, including 543,000 shares held indirectly through the Orohena Trust. The sale followed a standout quarter in which IQVIA reported second-quarter revenue of $4.37 billion, a 12.1% increase in adjusted earnings per share to $3.15, and record clinical bookings of $3.15 billion, while raising full-year guidance to as much as $17.475 billion.
S&P 500 Futures Slip as Fed Rate Uncertainty Builds
S&P 500 futures edged lower in early Tuesday trading while Dow futures ticked up, as the US 10-year Treasury yield hovered near 4.64% ahead of this week's Federal Reserve decision. Markets are pricing in roughly a one-in-three chance of a rate hike now and about a 56% chance by September. US durable goods orders for June rose 0.3% and a core business investment gauge gained 0.9%, signaling continued corporate spending. Among individual movers, IQVIA Holdings jumped 13.94% after its second-quarter earnings and raised guidance, Incyte gained 9.30% on higher full-year sales guidance, and Sherwin-Williams climbed 8.25% following its quarterly results and buyback progress. On the downside, Sandisk fell 14.25%, Corning declined 12.10% after Citi lowered its price target, and Bloom Energy dropped 11.34%.
IQVIA Holdings Inc reported second-quarter total revenue of $4,368 million, an 8.7% increase on a reported basis, with adjusted diluted earnings per share of $3.15, up 12.1% year-over-year. R&D Solutions revenue rose 8.8% to $2,575 million, while Commercial Solutions revenue grew 8.6% to $1,793 million. The company posted adjusted EBITDA of $994 million, a 9.2% increase, and R&D Solutions net new bookings surged 19.3% to $3,150 million, yielding a book-to-bill ratio of 1.22. IQVIA raised its full-year revenue guidance to a range of $17,275 million to $17,475 million, representing growth of 5.9% to 7.1%, and expects full-year adjusted diluted EPS of $12.80 to $13. For the third quarter, the company guided revenue of $4.350 billion to $4.390 billion and adjusted diluted EPS of $3.19 to $3.29.
IQVIA beats Q2 estimates and raises full-year 2026 guidance
IQVIA reported second-quarter 2026 non-GAAP earnings of $3.15 per share, beating analyst estimates by 12 cents, while revenue of $4.37 billion grew 8.7% year-over-year and exceeded consensus by $70 million. Commercial Solutions revenue rose 8.6% to $1,793 million, and R&D Solutions revenue increased 8.8% to $2,575 million, with R&D Solutions net new bookings surging 19% to $3.15 billion for a book-to-bill ratio of 1.22. The company raised its full-year 2026 guidance, now projecting revenue between $17,275 million and $17,475 million, adjusted EBITDA between $4,000 million and $4,050 million, and adjusted diluted earnings per share between $12.80 and $13.00. The new revenue midpoint implies 6.5% growth, up from the prior 5.8% outlook, driven by approximately 100 basis points higher organic growth and a 50 basis point boost from M&A, partially offset by an 80 basis point unfavorable foreign exchange impact. Shares rose 5% in after-market trading.
Institutional Investors See Healthcare's AI Story as Overblown, Fishbone Survey Finds
A new survey from Fishbone Advisors finds that institutional investors believe healthcare's AI narrative is overblown, with 48% to 67% of investors in every subsector saying management overemphasizes AI relative to its actual financial contribution. The quarterly Fishbone Healthcare Benchmarking Study, which surveyed 75 institutional investors active in healthcare, also shows that AI has yet to register as a material valuation driver in any subsector, a result unchanged on retest six months later. Eli Lilly leads the first published investor-assigned AI scores for 30 large-cap healthcare companies at plus 78, followed by UnitedHealth at plus 72 and Moderna at plus 64. Healthcare specialists are the least persuaded, with only 33% expecting AI to significantly influence valuations within three years, compared to 51% of generalist investors. Despite the skepticism, 81% of surveyed investors say they are positive on healthcare over the coming year.
IQVIA Holdings Outshines Penumbra as the Better Value Stock
IQVIA Holdings emerges as the more attractive value pick over Penumbra in the Medical - Instruments sector, according to Zacks Investment Research. IQVIA holds a Zacks Rank of #2 (Buy) with an improving earnings outlook, while Penumbra carries a Zacks Rank of #5 (Strong Sell). Valuation metrics further support the case: IQVIA has a forward P/E of 16.21, a PEG ratio of 1.61, and a P/B of 5.55, earning a Value grade of B. In contrast, Penumbra shows a forward P/E of 63.35, a PEG ratio of 1.97, and a P/B of 8.51, resulting in a Value grade of F.
Artisan Mid Cap Value Fund Says AI Concerns on IQVIA Holdings Likely Overstated
Artisan Mid Cap Value Fund initiated a new position in IQVIA Holdings during the first quarter of 2026, viewing recent share price weakness driven by AI disruption fears and soft CRO demand as a potential buying opportunity. The fund believes AI concerns are likely overstated given IQVIA's proprietary data assets and domain expertise, which position the company as a potential beneficiary of AI adoption rather than a casualty. IQVIA combines a leading global contract research organization franchise with a unique healthcare data asset, creating a diversified model with both cyclical and recurring revenue streams. At 15 times forward earnings and a high-single-digit free cash flow yield, the stock reflects low expectations despite resilient fundamentals. The fund's investor class returned negative 4.93% in the quarter, trailing the Russell Midcap Value Index's 3.68% gain.
IQVIA Stock Jumps 5.8% After Baird Raises Price Target to $249
Shares of IQVIA jumped 5.8% in afternoon trading after Baird raised its price target on the stock to $249 from $230 and designated it a 'bullish Fresh Pick'. The firm maintained its 'Outperform' rating, citing the clinical trials market's transformation driven by artificial intelligence, where IQVIA is seen as a key player poised to benefit from the industry's shift toward AI-integrated solutions.
Pharmacovigilance Automation Market to Reach USD 5.25 Billion by 2035
The global pharmacovigilance automation market is projected to grow from USD 2.80 billion in 2025 to USD 5.25 billion by 2035, at a compound annual growth rate of 6.50 percent. Software held a 72.40 percent share of the market in 2025, while the services segment is the fastest growing at a CAGR of 8.77 percent. Cloud-based deployment accounted for 49.80 percent of the market in 2025, and the SaaS segment is expected to record the highest CAGR of 13.02 percent. Artificial intelligence dominated with a 41.30 percent share in 2025, and natural language processing is the fastest growing technology segment at a CAGR of 13.73 percent. Pharmaceutical companies led end users with a 58.60 percent share in 2025, while biotechnology companies are the fastest growing at a CAGR of 11.57 percent. North America held a 38.60 percent share of the global market in 2025, and the Asia-Pacific region is the fastest growing regional market with a CAGR of about 8.92 percent.
IQVIA Holdings faces growth challenges and softer demand, raising questions about its data-driven pharma enablement story
IQVIA Holdings is under scrutiny as recent commentary highlights ongoing growth challenges, with revenue increases lagging peers and constant-currency trends pointing to softer demand and pressure on market share. The company's narrative projects $19.7 billion in revenue and $2.0 billion in earnings by 2029, requiring 5.8% yearly revenue growth and a roughly $0.6 billion earnings increase from $1.4 billion today. Some of the most pessimistic analysts already expected only about 5.4 percent annual revenue growth to roughly $19.5 billion and earnings near $1.8 billion by 2029, so this softer demand news could reinforce their concern that high leverage and slower growth might both worsen from here. IQVIA's May 2026 move to raise about $950 million in new senior notes to refinance existing debt is especially relevant, as elevated leverage and refinancing needs could collide with the capacity to keep investing in AI, data platforms, and higher-value services. The stock's fair value is estimated at $226.95, representing a 33% upside to its current price.
Oscar Health Touted as Top Pick While Inspire Medical and IQVIA Are Flagged for Caution
StockStory highlights Oscar Health as a healthcare stock with impressive fundamentals while recommending caution on Inspire Medical Systems and IQVIA. Oscar Health, with a market cap of $8.71 billion, posted annual revenue growth of 42.6% over the last two years and EPS compounding at 31.5% annually over four years, alongside a free cash flow margin expansion of 19.9 percentage points. In contrast, Inspire Medical Systems faces an estimated 8% sales decline and trades at 42.3x forward P/E on a $1.22 billion market cap, while IQVIA's 5.1% annual revenue growth and stagnant free cash flow margin raise concerns, with shares at $167.81 and a 12.8x forward P/E.
Global Decentralized Clinical Trials Market Projected to Reach USD 38.3 Billion by 2035
The global decentralized clinical trials market is projected to grow from USD 9.9 billion in 2025 to USD 38.3 billion by 2035, at a compound annual growth rate of 14.5%, according to a new report by Healthcare Foresights. The oncology segment held the largest market share of over 45% in 2025, driven by the integration of remote patient engagement and telemedicine in cancer research. Pharmaceutical and biotech sponsors accounted for more than 55% of the market in 2025, as they increasingly adopt decentralized and hybrid trial models to reduce costs and improve patient recruitment. North America led the market in 2025, while the Asia-Pacific region is expected to grow at the fastest rate due to cost advantages and technological readiness. Key players include ICON plc, Thermo Fisher Scientific, IQVIA Inc., and Oracle Health Sciences.
Medical Affairs Outsourcing Market to Reach USD 4.18 Billion by 2035
The global medical affairs outsourcing market is projected to grow from USD 2.10 billion in 2025 to USD 4.18 billion by 2035, at a compound annual growth rate of 7.16 percent, according to a report by SNS Insider. North America held the largest share in 2025 at over 41.85 percent, with the U.S. market alone valued at USD 0.64 billion and expected to reach USD 1.06 billion by 2035. By service type, medical writing accounted for the largest share at 31.45 percent, while pharmacovigilance is the fastest-growing segment at a CAGR of 11.55 percent. Oncology led among therapeutic areas with a 33.87 percent share, and pharmaceutical companies were the dominant client type at 49.68 percent of the market. Full-service outsourcing was the preferred engagement model, representing 54.73 percent of the market in 2025.
Morgan Stanley upgrades Charles River, downgrades IQVIA on diverging CRO outlooks
Morgan Stanley upgraded Charles River Laboratories to Overweight and downgraded IQVIA Holdings to Equal-weight on Wednesday, June 17. The bank raised its Charles River price target to $220 from $185, citing increased biopharma funding that benefits the company's higher exposure to small and mid-sized biotech clients, which account for 40% to 45% of its revenue. IQVIA's target was cut to $200 from $225, with Morgan Stanley flagging a risk that pharmaceutical companies could move about 30% of typical trial costs in-house using artificial intelligence, reducing demand for its services. The downgrade also noted that much of IQVIA's earnings growth since 2022 has come from stock buybacks rather than faster sales. In a related transaction, IQVIA is buying European drug discovery assets from Charles River for roughly $145 million in cash, a deal expected to close this quarter.
IQVIA Shares Fall 19.8% Over Six Months, Underperforming S&P 500
IQVIA shares have dropped 19.8% over the last six months to $177.52, contrasting with the S&P 500's 12.4% gain. The company's annualized revenue growth of 6.7% over five years fell short of healthcare sector benchmarks, while constant currency revenue growth averaged 4.5% over two years, slightly lagging the sector. Its trailing 12-month free cash flow margin remained unchanged at 12.7% over five years. The stock trades at 13.6 times forward price-to-earnings, but analysts cite shaky fundamentals as presenting too much downside risk.